Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Article in Russian | MEDLINE | ID: mdl-11081269

ABSTRACT

160 patients over 60 years of age appealed to gerontologic unit of out-patient psychiatric clinic for the first time. The patients were divided into two main groups: with organic mental disorders (OMD) and with functional mental disorders (FMD) (79 and 81 patients, respectively). In the group of OMD the main form of disturbances were cases with dementia (74.4%) mainly of the Alzheimer's type, and cerebral vascular dementia. In 25.3% of the patients the cognitive disturbances didn't attain the level of dementia. In a group of patients with different forms of dementia a high frequency of comorbid mental pathology was observed (83%)--confusional states, delusions, depressive conditions as well as disturbed behavior (67.7%) that was one of the reasons for consulting a psychiatrist. In FMD group the prevailing pathology were depressions, both of the major (37.1%) and mild (34.6%) forms. The remaining cases were characterized by delusions (10.1%), anxiety-phobic (7.6%) states and somatoform disturbances (5.1%). Among the patients both of OMD and FMD groups it was possible to diagnose approximately 3-4 different somatic diseases; vascular and gastrointestinal disorders were met more frequently. The study of contribution of brain computer tomography (CT) to diagnosis of mental pathology (according to ICD-10), has demonstrated that in 30.8% of the cases it was decisive, in 41% it confirmed the clinical data and in 21.8% CT provide additional data (detecting latent cerebral vascular damage). And only in 6.4% of the cases CT fails to give definite information in diagnostically complicated cases. In 26.6% of the patients with FMD, CT of brain had detected symptoms of mild vascular pathology.


Subject(s)
Cerebrovascular Disorders/diagnosis , Cerebrovascular Disorders/epidemiology , Mental Disorders/diagnosis , Mental Disorders/epidemiology , Office Visits , Aged , Aged, 80 and over , Cerebrovascular Disorders/complications , Comorbidity , Female , Geriatric Assessment , Humans , Male , Mental Disorders/etiology , Middle Aged , Severity of Illness Index , Somatoform Disorders/diagnosis , Somatoform Disorders/epidemiology
2.
Article in Russian | MEDLINE | ID: mdl-11517474

ABSTRACT

Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism. 30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale. Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days. Significant decrease of the severity of extrapyramidal symptoms (according to the Scales used) was observed by the end of the course of therapy. The number of the responders was 46.6%, of the partial responders--26.6%. Efficiency of cerebrolysin was the same both in the groups of patients with drug-induced parkinsonism (number of the responders--54.5%) and in patients with tardive dyskinesia (the responders' number--60%). The efficiency of cerebrolysin was lower in patients with combination of symptoms of parkinsonism and tardive dyskinesia as well as in ones with pronounced negative schizophrenic disorders in clinical picture. Efficacy of cerebrolysin was also the same in patients of both middle and old age. Its efficiency was equally high independently on the duration of extrapyramidal disorders' existence.


Subject(s)
Amino Acids/therapeutic use , Antipsychotic Agents/adverse effects , Dyskinesia, Drug-Induced/drug therapy , Dyskinesia, Drug-Induced/etiology , Neuroprotective Agents/therapeutic use , Nootropic Agents/therapeutic use , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/drug therapy , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Amino Acids/administration & dosage , Dyskinesia, Drug-Induced/diagnosis , Female , Humans , Male , Middle Aged , Neuroprotective Agents/administration & dosage , Nootropic Agents/administration & dosage , Parkinsonian Disorders/diagnosis , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...